PTC Therapeutics | PTCT - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Cytokinetics USD 207.8M 7.22M 2026-06
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 3.95B 19.57B 2026-06
Incyte USD 973.64M 4.65B 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
Karyopharm Therapeutics USD 61.83M 9.9M 2026-03
Novartis USD 10.2B 912M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
TG Therapeutics USD 218.66M 48.54M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06
Xencor USD 87.82M 5.44M 2026-06